Vaginal microbicides containing antiretrovirals (ARVs) have shown to prevent vaginally acquired human immunodeficiency virus (HIV), but these products may not protect women who engage in anal sex. Intravaginal dosing with ARVs has shown to result in drug exposures in rectal tissues, thus raising the possibility of dual compartment protection. To test this concept, we investigated whether intravaginal dosing with emtricitabine (FTC)/tenofovir (TFV) gel, which fully protected macaques against repeated vaginal exposures to simian human immunodeficiency virus (SHIV), protects against rectal SHIV exposures. Pharmacokinetic studies revealed rapid distribution of FTC and TFV to rectal tissues and luminal fluids, albeit at concentrations 1-2 log 10 lower than those in the vaginal compartment. Efficacy measurements against repeated rectal SHIV challenges demonstrated a 4.5-fold reduction in risk of infection in macaques that received intravaginal FTC/TFV compared to placebo gel (P = .047; log-rank test). These data support the concept of dual compartment protection by vaginal dosing and warrants developing ARV-based vaginal products with improved bidirectional dosing.
An estimated 1.8 million new human immunodeficiency virus (HIV) infections were reported worldwide in 2016, with the majority acquired by women [1] . Vaginal microbicides formulated with antiretroviral (ARV) drugs are being developed as on-demand or sustained-release products that can be administered vaginally to protect women at high risk of acquiring HIV [1] [2] [3] [4] [5] [6] . The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 study in South Africa was the first to demonstrate that a vaginal gel containing 1% tenofovir (TFV) could reduce a women's risk of contracting HIV by 39% overall and 54% among those who were adherent to product use [7] . Two recent studies assessing the efficacy of an intravaginal ring releasing dapivirine also showed reductions in HIV incidence by 27%-31% in the dapivirine group compared to placebo [4, 8] . A pipeline of ARV delivery platforms including novel vaginal rings, films, and inserts are being developed for preventing HIV infections in women [4, 6, 9, 10] . However, these products are all designed to prevent vaginal HIV transmission and do not address risks of women acquiring HIV infection through anal sex. Although self-reported frequency of anal sex in the CAPRISA 004 and dapivirine intravaginal ring trials was low (<1% and 2%-6%, respectively), it is important to understand how anal intercourse could affect efficacy of these products [4, 7] . Transmission of HIV is more efficient through unprotected rectal than vaginal sex, thus highlighting the importance of developing topical products that can protect women against both mucosal routes of infection [11] .
Anal intercourse is practiced by many women, and evidence suggests the numbers are increasing [12] [13] [14] [15] . Recent reports suggest potential motivations for women to engage in anal sex including a personal desire for the act, pleasing a male partner, financial and drug exchange, avoiding pregnancy, preserving virginity, and belief that anal sex is less risky than vaginal sex [16] . A study conducted in 2015 among heterosexual women in the United States estimated the proportion of the HIV burden attributable to anal sex in women of all ages was 28% and nearly 40% in younger women [12] . Moreover, pooled per-act transmission risk probabilities derived from 3 meta-analyses of >15 relevant studies concluded that per-act risk (per 10 000 exposures) for HIV acquisition from receptive anal sex (0.0138) is at least 16-fold that for receptive vaginal sex (0.0008), which suggest that women who engage in both practices are at the highest risk [12, 17, 18] . The higher rectal transmission rate is likely explained by physiological differences between vaginal and rectal tissues, including higher density of immune cells and a single columnar epithelium that may be more susceptible to trauma associated with sex. This differential in the HIV transmission risk is concerning, particularly for developing ARV-based vaginal microbicides that may provide high protection against vaginal HIV exposures but offer little to no protection against rectal HIV exposures.
The efficacy of vaginal microbicides such as TFV gel is strongly related to their ability to rapidly deliver drug to cervicovaginal tissues at concentrations that are at least 100 times as high as oral dosing as demonstrated in women and preclinical macaque models [19] [20] [21] . These pharmacokinetics (PK) studies have also revealed bidirectional drug distribution whereby administration of a vaginal TFV gel resulted in rapid accumulation of TFV in neighboring rectal tissues [19, 22] . While the findings raise the possibility of rectal protection by vaginal dosing, they also show lower drug concentrations in the rectum and, thus, it is unclear if such levels are sufficient to protect against rectal HIV acquisition. Given the difficulty of addressing this question in women, preclinical macaque models can be used to assess if a highly potent vaginal gel can effectively deliver drugs to rectal tissues at concentrations that prevent rectal infection.
We have developed simian human immunodeficiency virus (SHIV) macaque models of rectal and vaginal transmission that use repeat low-dose (RLD) SHIV exposures to better mimic populations at high risk of HIV infection. We have successfully used these models to test efficacy of several topical and systemic preexposure prophylaxis and postexposure prophylaxis modalities [3, 20, 21, [23] [24] [25] . In the RLD model, protection is measured by the ability of the intervention to prevent or delay SHIV infection relative to untreated controls. These models predicted the clinical efficacy of oral tenofovir disoproxil fumarate (TDF) in combination with emtricitabine (FTC) and demonstrated high protection by a vaginal gel containing 1% TFV that was related to high and sustained drug concentrations in vaginal tissues [20, 23, 26] . Likewise, the models have been successfully used to assess in vivo PK and efficacy of rectal gel formulations containing TFV [24] . Given these preclinical data and the availability of suitable macaque models, we sought in this study to test the concept of bidirectional protection by a potent 2-drug vaginal gel containing 1% TFV and 5% FTC [27] . We selected this gel formulation as it was fully protective against vaginal transmission and could thus be used to assess reductions in efficacy by rectal exposures. Here we show that vaginal administration of the FTC/TFV gel resulted in rapid and high drug exposures in the rectal compartment that reduced the risk of SHIV infection by 4.5-fold in treated macaques compared to controls. These findings provide the first proof of concept of rectal protection by intravaginal dosing and will inform the development of vaginal products with improved bidirectional protection.
METHODS

Gel Formulations and Virus Stock
A 2% hydroxyethyl cellulose (HEC) gel was formulated without (placebo) and with 5% FTC and 1% TFV (wt/wt) at pH 6.5 as previously described [27, 28] . Macaques were administered 3 mL of gel (FTC [150 mg]/TFV [30 mg]) vaginally in the PK and efficacy studies described below. The SHIV 162P3 virus stock was prepared at 50% tissue culture infective dose (TCID 50 ) of 50 TCID 50 /mL as previously described [20] . Individual challenge stocks were stored as 1-mL aliquots in liquid nitrogen and thawed prior to each rectal challenge.
PK Assessment Following Intravaginal FTC/TFV Dosing
We first defined extracellular FTC and TFV in rectal and vaginal fluids following intravaginal gel dosing. Pharmacokinetic drug distribution was evaluated in 6 normal cycling pigtailed macaques that received 3 mL of FTC/TFV gel. To account for inter-and intravariability between animals and to increase the number of measurements for each time point, intravaginal dosing was repeated in the same macaques for a total of 3 doses, each separated by a 1-week resting period. Blood plasma, vaginal fluids, and rectal fluids were collected at 0.5, 2, 6, and 24 hours postdosing. Rectal and vaginal fluids were collected with Weck-Cel Surgical Spears (Medtronic Ophthalmic) using a modification of an established protocol used for collecting rectal secretions [29] . Drug levels in fluids eluted from spears were corrected for their respective net weight and reported as nanograms per milliliter. The concentrations of FTC and TFV were measured as previously described using validated high-performance liquid chromatography-tandem mass spectrometry methods with a lower limit of detection of 5 ng/mL [20, 21, 29] .
We also measured intracellular FTC triphosphate (FTC-TP) and TFV diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) and mononuclear cells from rectal and vaginal tissues. This analysis was done in a separate group of 2 drug-naive macaques that were SHIV infected and scheduled for euthanasia. This approach allowed for collecting large quantities of tissues for cell enrichment that were otherwise unattainable in a live animal. In brief, macaques received 3 mL of FTC/TFV gel vaginally 2 hours prior to euthanasia. Excised tissue sections from each animal were subjected to enzymatic digestion and crude cell extracts were spun through lymphocyte separation medium (MP Biomedicals) to enrich for mononuclear cells as previously described [20, 21] . TFV-DP and FTC-TP levels were measured using an automated online weak anion-exchange solid-phase extraction method coupled with ion-pair chromatography-tandem mass spectrometry as previously described [20] . Results are expressed as femtomoles per million cells.
Efficacy of FTC/TFV Gel Against Rectal SHIV Challenge Following Vaginal Dosing
Efficacy was evaluated in pigtailed macaques using the same SHIV stock, gel formulation, and intravaginal dosing procedures that provided complete protection to macaques against vaginal SHIV infection [27] . In brief, 6 macaques received 3 mL of gel containing either HEC or FTC/TFV intravaginally 30 minutes before rectal challenge with 1 mL of working SHIV stock (50 TCID 50 ). Intravaginal dosing and rectal challenges were performed twice per week (every 3-4 days) for up to 5 weeks or 10 rectal challenges. To ensure all challenges were treated equally with respect to timing of pre-and postdosing between challenges, macaques received twice-weekly gel dosing 2 weeks prior to the start of the first challenges. Blood was collected within 30 minutes after dosing to monitor for drug levels and SHIV infection by reverse-transcription polymerase chain reaction (PCR) (sensitivity = 50 copies/mL). To account for the lag period between virus infection and detection of SHIV RNA in plasma, time of infection was reported as 1 week or 2 SHIV challenges prior to the first confirmed SHIV RNA detection [30] . Infected macaques continued to receive twice-weekly dosing for 6-8 weeks postinfection. Drug resistance emergence was monitored using genotypic screening (sensitive real-time PCR assay) for the FTC-and TFV-associated M184V and K65R mutations, respectively, as described previously [26, 31] . All studies adhered to the Guide for the Care and Use of Laboratory Animals (Institute for Laboratory Animal Research, 1996) and were approved by the Institutional Animal Care and Use Committee of the Centers for Disease Control and Prevention.
Statistical Methods
Pharmacokinetic parameters for FTC and TFV measured in plasma and vaginal and rectal fluids were estimated by noncompartmental analysis using GraphPad Prism 5 (version 5.04) and unless otherwise indicated, presented as the median values. The median and interquartile range values are presented in graphs. Parameters include maximum concentration, time for peak, and area under the concentration-time curve from time 0 to 24 hours (AUC 0-24h ). Assuming constant risk per SHIV challenge, efficacy was estimated based on the number of infections per total exposures in the treatment group relative to placebo controls. For a time-to-event analysis, survival methods were conducted. First, survival curves were plotted to compare cumulative percentage of uninfected macaques as a function of the number of rectal challenges by study arm. Additionally, a Cox proportional hazards model was estimated to investigate whether there was evidence of an increasing trend in the number of challenges in the treatment group compared to the placebo group over time. A likelihood ratio test was used for the Cox model with an α < .05 as a threshold to reject the null. The magnitude of peak viral replication in plasma between treatment and control groups was compared using the Wilcoxon-Mann-Whitney test (2-sided).
RESULTS
PK Profiles Following Intravaginal or Intrarectal FTC/TFV Gel
We assessed the distribution of FTC and TFV in plasma and vaginal and rectal fluids following intravaginal FTC/TFV gel dosing. The FTC and TFV concentration-vs-time curves in each compartment are shown in Figure 1A . Both FTC and TFV were detected in the plasma and rectal fluids within 30 minutes after intravaginal dosing and reached maximal concentrations by 2 hours. The median peak concentrations of FTC and TFV in the vaginal compartment (4.2 × 10 6 ng/mL and 1.6 × 10 6 ng/mL, respectively) were at least 1-2 orders of magnitude higher than those in the rectal compartment (4.1 × 10 4 and 1.8 × 10 4 ng/mL, respectively) and 5 orders of magnitude above those in plasma (21 ng/mL and 11 ng/mL, respectively). The median AUC 0-24h values for FTC and TFV in rectal fluids were high (1.3 × 10 6 and 5.3 × 10 5 ng × hour/mL, respectively), albeit lower than in vaginal fluids (2.1 × 10 7 and 6.5 × 10 6 ng × hour/mL, respectively). We also calculated the AUC 0-24h ratios as a measure of relative drug exposure in the rectal and vaginal lumen. The rectal:vaginal ratios for FTC and TFV were similar (0.06 and 0.08, respectively) and within the range previously described in rhesus macaques following intravaginal dosing with TFV gel [22] . TFV-DP and FTC-TP levels in PBMCs, vaginal, and rectal mononuclear cells were defined in 2 additional macaques. Figure 1B shows detectable TFV-DP and FTC-TP concentrations at 2 hours in rectal lymphocytes from both animals (mean = 207 and 404 fmol/10 6 cells, respectively), albeit at lower levels compared to those in vaginal lymphocytes (mean = 10 983 and 588 fmol/10 6 cells, respectively). TFV-DP or FTC-TP was not detected in PBMCs.
Efficacy of Intravaginal Administration of FTC/TFV Gel in Preventing
Rectal SHIV Transmission
We next investigated the ability of intravaginal gel dosing to prevent rectal SHIV infection. Figure 2 shows the cumulative percentage of uninfected macaques as a function of the number of rectal SHIV exposures received. All 6 macaques treated vaginally with placebo gel were infected after a median of 3.5 rectal exposures (range, 1-9). In contrast, 5 of the 6 macaques dosed vaginally with FTC/TFV gel were SHIV negative for up to 8 challenges, 4 of which remained SHIV negative up to challenge 10. Relative to placebo controls, the risk of infection was at least 4.5-fold lower (P = .047; Cox proportional hazard ratio) in treated macaques, demonstrating that the drug exposures in rectal tissue from intravaginal FTC/TFV dosing provided protection against repeated rectal SHIV exposures.
Longitudinal assessment of drug levels measured in plasma collected twice weekly during the study period revealed low and transient systemic FTC and TFV exposures in all macaques (Figure 3 ). Of the 154 plasma samples collected, FTC was detected more frequently (95% vs 33%) and at higher concentrations than TFV. Consistent with previous findings in cycling pigtailed macaques, the FTC and TFV levels in plasma fluctuated over time, likely reflecting temporal changes in systemic drug levels associated with the different stages of the menstrual cycle [20, 27] .
To better understand if the systemic or local drug absorption from 2 gel applications per week affected the virologic outcome or selected for drug-resistant viruses, virus replication was monitored in infected macaques that continued to receive placebo or FTC/TFV gel twice weekly for up to 6 weeks after the first RNA detection. Figure 4 shows that the median peak viremia (6.4 log 10 copies/mL) in the breakthrough infections were significantly lower (~1.8 logs) than in the placebo controls (8.1 log 10 copies/mL; P = .03). Likewise, the median viremia AUC values 1-7 weeks postinfection were lower in the breakthrough compared with placebo controls (28.5 and 34.6 log 10 RNA copies × week/mL, respectively). However, despite the blunted viremia, allele-specific sensitive PCR showed no evidence of M184V or K65R emergence in viruses detected in plasma of the breakthrough infections at the time of infection, peak viremia, or during a follow-up period of 6-8 weeks.
DISCUSSION
Vaginal microbicides are designed to protect women from vaginally but not rectally acquired HIV infections. The increased recognition of anal sex practices among women challenges topical product development to confer dual protection in women against both vaginal and rectal HIV infection. In this study, we tested the concept of dual protection by vaginal product. We show that intravaginal administration of a potent gel containing TFV and FTC, which fully protected against vaginal SHIV infection [27] , resulted in rapid dissemination of both FTC and TFV to the rectal compartment and TFV-DP and FTC-TP in rectal lymphocytes. We also show significant delay in rectal SHIV infections in macaques following intravaginal dosing with FTC/TFV compared to placebo gel. Taken together, our findings support the development of ARVs and delivery platforms with improved bidirectional dosing properties for dual protection.
Our PK studies measured drug distribution in the rectal lumen and the pharmacologically active drug metabolites in tissues. These studies revealed high drug exposures in rectal tissues, albeit approximately 1-2 logs lower than in vaginal tissue. While the exact mechanism of vaginal-to-rectal drug distribution is unclear, it likely involves diffusion of drugs from adjacent vaginal tissues rather than distribution through blood, as commonly observed with oral drug dosing. Local drug diffusion is consistent with the rapid and high concentrations of TFV and FTC in the rectal lumen, the transient and low concentrations of both drugs in the plasma, and the 2 active drug metabolites FTC-TP and TFV-DP detected in rectal lymphocytes but not in PBMCs. Furthermore, we note that oral administration of FTC and TDF to macaques results in higher plasma exposures of FTC and TFV than with vaginal gel dosing but much lower levels in rectal fluids, further supporting local diffusion as a primary mechanism of rectal tissue dosing [23] . Our findings in this study have important implications for developing vaginally applied products that effectively distribute drug to both the vaginal and rectal compartments. These products will likely require unique formulations that consist of highly potent single or multiple drug combinations with enhanced permeability to rapidly diffuse and cover a large surface area in the rectum. An alternative approach for dual protection includes developing topical products such as gels and solid dosage forms (ie, inserts, tablets, suppositories) with universal formulations suitable for both vaginal and rectal use [32] . We and others have previously reported that 1% TFV gel applied rectally before SHIV challenge protected macaques from infection, thus supporting the concept of rectal efficacy by topically delivered ARVs [24, 33] . Consistent with these findings, we show here that FTC and TFV delivered to the rectum indirectly by vaginal-to-rectal dosing significantly delayed infections in macaques repeatedly exposed rectally to SHIV. We note that the lower protection by intravaginal FTC/TFV gel against rectal compared to vaginal SHIV exposure was largely attributed to 4 macaques that were all infected late in the challenge phase (10 exposures). The reasons for these late failures are not clear. As previously documented in cycling pigtailed macaques following intravaginal ARV-gel dosing, examination of plasma drug concentrations during the challenge and follow-up period revealed temporal changes in systemic drug absorption [3, 20, 27] . It is possible that the physiological changes of the vaginal epithelium due to the menstrual cycle influenced tissue permeability and thus the bioavailability of drug in the rectum. Whether other pharmacologic factors at the rectal mucosa, such as modulations of drug transporter (efflux/influx) pathways, led to decreased rectal drug exposures is also not known [34] . Alternatively, recruitment of target cells to the rectum in response to repeated SHIV exposures may have increased susceptibility to infection [35] . Lower viral loads were observed in animals with breakthrough infections that continued to receive FTC/TFV gel twice weekly for several weeks after becoming infected. The lower viral loads were likely attributed to the systemic antiviral activity of both FTC and TFV. However, despite the lower viral loads in the breakthrough infections and twice-weekly FTC/TFV dosing, results of highly sensitive allele-specific PCR assays found no evidence of the FTC-or TFV-associated drug resistance mutations in all 6 breakthrough infections. It is plausible that the short duration of gel dosing and the associated antiviral activity was not optimal for drug resistance selection.
In summary, we show that intravaginal dosing with FTC/TFV gel in macaques resulted in rapid drug distribution in the rectal compartment that significantly delayed rectal SHIV infection in the treatment group compared to controls. Our analysis supports the concept of vaginal formulations that can provide dual vaginal and rectal protection from HIV and provide preclinical PK and efficacy tools in macaque models to facilitate clinical development of improved vaginal products for high bidirectional efficacy. 
